tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
Tara Speranza

Tara Speranza

Bell Potter
Wall Street Analyst
Ranked #6,087 out of 8,047 Analysts on TipRanks (#16,083 out of 21,521 overall experts)

Success Rate

0%
0 out of 2 Profitable Transactions

Average Return

-13.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Tara Speranza's ratings since 2022 and opened each position for the duration of 1 Year:
0.00% of your transactions would have been profitable with an average return of -13.7%

Stock Rating Distribution

8Ratings
87.50% Buy
12.50% Hold
0.00% Sell
Distribution of Tara Speranza's ratings

Additional Information

Main Sector:General
Geo Coverage:
AustraliaAustralian Market
United StatesUS Market

Best Rating

Stock:
Lumos Diagnostics Holdings Ltd.
(LDX)
Rating Type:Buy
Dates:Aug 05, 2022 - Jan 01, 1970
Gain:0.00%
The most profitable rating made by Tara Speranza

Tara Speranza's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Immutep Ltd
Jun 07, 2022
Buy
Reiterated
$0.46
(101.45% Upside)
0%
-13.75%
2
Actinogen Medical Limited
Jun 23, 2022
Buy
Reiterated
$0.03
(21.31% Upside)
0.00%
1
Microba Life Sciences Limited
Jul 20, 2022
Hold
Reiterated
A$0.34
(41.67% Upside)
0.00%
1
Lumos Diagnostics Holdings Ltd.
Aug 05, 2022
Buy
Reiterated
A$0.10
(33.33% Upside)
0.00%
4
List of latest recommendations made by Tara Speranza. Click to expand and see Tara Speranza's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More